Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.63 |
| ▸ | CES1 | P23141 | 2/20 | 0.63 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.63 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717831 | 0.95 | NPC1 (0.70) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL3517537 | 0.90 | NPC1 (0.68) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL15291004 | 0.86 | NPC1 (0.59) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL5717616 | 0.85 | NPC1 (0.66) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL1810603 | 0.84 | NPC1 (0.57) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL7979853 | 0.84 | NPC1 (0.64) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL12380049 | 0.82 | NPC1 (0.69) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL4034138 | 0.81 | NPC1 (0.65) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL5206454 | 0.81 | NPC1 (0.63) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 | |
| SCHEMBL6384896 | 0.80 | NPC1 (0.63) | NPC1SMN1; SMN2RAB9AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546581-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546581-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546581-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110190205-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190205-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190205-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7947841-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947841-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947841-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090239798-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239798-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239798-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20070293423-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | ELI LILLY AND COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1658285-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1658285-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1658285-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005019212-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293423-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | NPC1 1211/4885SMN1; SMN2 3102/4885RAB9A 1969/4885 |
| US-20090239798-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | NPC1 1326/4885SMN1; SMN2 3372/4885RAB9A 2227/4885 |
| US-20110190205-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | NPC1 1326/4885SMN1; SMN2 3372/4885RAB9A 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.